BOOST Pharma’s €3.1M Bet on Early Intervention for Brittle Bone Disease
Stockholm-based BOOST Pharma has raised €3.1 million to accelerate development of its pioneering stem cell therapy for osteogenesis imperfecta. The funding reflects growing European investment in advanced cell therapies targeting rare pediatric diseases with early intervention strategies.